Clinical Trials Browser

Resectable Colon Cancer

Metastatic Adenocarcinoma of the Pancreas

Colonic Neoplasms, Rectal Neoplasms

Adenocarcinoma Of Esophagus, Parkinson Disease 4, Autosomal Dominant Lewy Body, Esophageal Neoplasms, Stomach Neoplasms

Parkinson Disease 4, Autosomal Dominant Lewy Body, Colorectal Neoplasms

Pancreatic Neoplasms

Colonic Neoplasms, Colorectal Neoplasms, Hereditary Nonpolyposis, DNA Repair-Deficiency Disorders

Rectal Neoplasms

Colonic Neoplasms

Colorectal Neoplasms

Urinary Bladder Neoplasms

Colorectal Neoplasms

Colorectal Neoplasms

Adenocarcinoma Of Esophagus, Adenocarcinoma, Esophageal Neoplasms, Stomach Neoplasms

HER2-positive Gastric Cancer

Pancreatic Neoplasms

Urinary Bladder Neoplasms

Colorectal Neoplasms

Adenocarcinoma Of Esophagus

Colorectal Neoplasms

Clinical Stage I Esophageal Adenocarcinoma AJCC v8

Adenocarcinoma, Neoplasms

Adenocarcinoma Of Esophagus, Stomach Neoplasms

PRETEXT I Hepatoblastoma

Pancreatic Neoplasms

Clinical Trials

Neoadjuvant/Adjuvant AK104 in Microsatellite Instability-high or Mismatch Repair-deficient, Resectable Colon Cancer

NAPOLI 3

KANDLELIT-012

HERIZON-GEA-01

MK-3475-C66

A Study to Evaluate the Effectiveness and Safety of Setidegrasib, Given With Either mFOLFIRINOX or NALIRIFOX Chemotherapies, in People With Pancreatic Cancer

Combination Chemotherapy With or Without Atezolizumab in Treating Patients With Stage III Colon Cancer and Deficient DNA Mismatch Repair

NEO-RT

Oxaliplatin, Leucovorin, and Fluorouracil With or Without Bevacizumab in Treating Patients Who Have Undergone Surgery for Stage II Colon Cancer

Testing the Addition of Atezolizumab to Combination Chemotherapy or Atezolizumab Alone for Metastatic Colon or Rectal Cancer, the COMMIT Study

Chemoradiotherapy With or Without Atezolizumab in Treating Patients With Localized Muscle Invasive Bladder Cancer

OrigAMI-2

OrigAMI-3

Sonesitatug Vedotin in Combination With Capecitabine With or Without Rilvegostomig in Participants With Advanced or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma Expressing Claudin18.2

A Phase Ⅲ Study of Rilvegostomig in Combination With Fluoropyrimidine and Trastuzumab Deruxtecan as the First-line Treatment for HER2-positive Gastric Cancer

LAP100

Testing Shorter Duration Radiation Therapy Versus the Usual Radiation Therapy in Patients Receiving the Usual Chemotherapy Treatment for Bladder Cancer, ARCHER Study

MOUNTAINEER-03

mFOLFIRINOX Versus mFOLFOX With or Without Nivolumab for the Treatment of Advanced, Unresectable, or Metastatic HER2 Negative Esophageal, Gastroesophageal Junction, and Gastric Adenocarcinoma

HARMONi-GI3

Comparing Proton Therapy to Photon Radiation Therapy for Esophageal Cancer

LUCERNA

STAR-221

Risk-Based Therapy in Treating Younger Patients With Newly Diagnosed Liver Cancer

Studying Chemotherapy With or Without Panitumumab for Unresectable, Locally Advanced, or Metastatic Pancreatic Cancer Without KRAS Mutations